PUBLICATIONS


Castera, L. Intérêt de l'élastométrie (FibroScan®) pour l'évaluation non invasive de la fibrose hépatique [Use of elastometry (FibroScan®) for the non-invasive staging of liver fibrosis]. Gastroenterologie Clinique et Biologique 2007;31(5):524-30.


Nguyen-Khac, E. Résultats et place du FibroScan® dans le diagnostic non invasif de la fibrose hépatique [Results and place of FibroScan® in the noninvasive diagnosis of liver fibrosis]. La Revue de médecine interne 2007;28(2):94-102.


Murtagh, J. and V. Foerster. La quantification non invasive de la fibrose hépatique par élastographie impulsionnelle ultrasonore (FibroScan®) [Transient elastography (FibroScan®) for noninvasive assessment of liver fibrosis]. Notes sur les technologies de la santé en émergence 2006;(90).


INTERNATIONAL COMMUNICATIONS


Rudler, M., P. Cluzel, et al. Transient elastography (FibroScan®) and hepatic venous pressure gradient measurement in patients with cirrhosis and gastrointestinal haemorrhage related to portal hypertension. 59th Annual Meeting of the American Association for the Study of Liver Disease. Oct. 31st–Nov. 4, 2008, San Francisco, CA, USA.


Schiefke, I., M. Wiese, et al. Correlation of transient elastography (FibroScan®) and hepatic artery doppler sonography in patients 30 years after single source hepatitis C genotype 1B outbreak in Germany. 59th Annual Meeting of the American Association for the Study of Liver Disease. Oct. 31st-Nov. 4, 2008, San Francisco, CA, USA.


Rudler, M., P. Cluzel, et al. Transient elastography (FibroScan®) and hepatic venous pressure gradient measurement
in patients with cirrhosis and gastrointestinal haemorrhage related to portal hypertension. 50th Anniversary/Meeting of the International Association for the Study of Liver. Oct 31st-Nov. 2nd, 2008, San Francisco, CA, USA.


Tokumo, H., Y. Asamoto, et al. Probulocul, a lipid-lowering agent with strong antioxidant properties, improves both clinical and histological findings in patients with non-alcoholic fatty liver disease. 50th Anniversary/Meeting of the International Association for the Study of Liver. Oct 31st-Nov. 2nd, 2008, San Francisco, CA, USA.


Klemmensen Mössner, B., T. Riis Jørgensen, et al. Outreach screening of drug users with FibroScan® identifies a high proportion of severe fibrosis not previously recognized. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27 2008, Milano, ITALY.


Arena, U., F. Vizzutti, et al. Transient elastography (TE) is more effective for the identification of HCV patients with advanced (F3-F4) rather than significant (F2-F4) liver fibrosis. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.


Marin-Gabriel, J. C., J. B. De-la-Cruz, et al. Failure of liver stiffness measurement with FibroScan®: prevalence and determinants. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.


Chan, H. L. Y., G. L. H. Wong, et al. Transient elastography (FibroScan®) can detect advanced liver fibrosis best among patients with normal alanine transaminase. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.

Wong, V. W., G. L. Wong, et al. Combination of the median and variability of liver stiffness measurements by transient elastography improves the accuracy of diagnosing advanced fibrosis in nonalcoholic fatty liver disease. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.

Marion, D., F. Bailly, et al. Comparative study of transient elastometry and hepatic vein transit time of a ultrasound contrast agent in fibrosing liver disease. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.


Abergel, A., C. Bonny, et al. FibroScan® measures according to intercostal space: validity and concordance. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.


Marin-Gabriel, J. C., J. B. De-la-Cruz, et al. Transient elastography (FibroScan®) in hepatitis C native liver vs. liver transplant recipients with recurrence: diagnostic performance and predictors of advanced fibrosis. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.

Bergmann, J. F., C. Verveer, et al. FibroScan® superior to Apri in detecting significant liver fibrosis in chronic hepatitis B and C patients. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.

Ferlitsch, A., M. Homonck, et al. Surveillance of Thiopurine induced nodular regenerative hyperplasia in patients with inflammatory bowel disease by transient elastography (FibroScan®) of the liver. 43rd Annual Meeting of the European Association for the Study of the Liver April 23rd -27, 2008, Milano, ITALY.


Afdhal, N. H., R. Malik, et al. Comparison of FibroScan®, APRI, AST/ALT and clinical signs as non invasive predictors of cirrhosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.


Bureau, C., M. Robic, et al. Prognostic value of liver stiffness measurement and hepatic venous pressure gradient in patients with chronic liver disease: a prospective study. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.
**Cales, P., J. Boursier, et al.** Comparison of reproducibility of histology, blood tests and FibroScan® for liver fibrosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Calvaruso, V., S. Maimone, et al.** Can platelet count or APRI be the poor man’s transient elastography in HCV patients? 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Castera, L., P. Bernard, et al.** What is the best non invasive method for early prediction of cirrhosis in chronic hepatitis C? Prospective comparison between FibroScan® and serum markers (Lok index, APRI, AST/ALT ratio, platelet count and Fibrotest). 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Castera, L., G. Sebastiani, et al.** Prospective comparison of two algorithms combining non invasive tests for staging of liver fibrosis in chronic hepatitis C. 58th Annual Meeting of the American Association for the Study of Liver Disease November 2nd-6, 2007, Boston, MA, USA.

**de Ledinghen, V., D. Laharie, et al.** Usefulness of FibroScan® for the follow up of patients treated with methotrexate. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**de Ledinghen, V., T. Lamireau, et al.** A dedicated FibroScan® probe to evaluated liver fibrosis in children: feasibility and performance for the diagnosis of cirrhosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Di Marco, V., F. Bronte, et al.** Iron overload does not effect the quantification of fibrosis by liver stiffness measurement. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Feitosa, F., S. Radenne, et al.** Comparison between hepatic elasticity measurements (FibroScan®) and liver biopsy in patients transplanted for HCV cirrhosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Fraquelli, M., C. Rigamonti, et al.** Bow body mass index (BMI) predicts discordance between transient elastography (TE) and liver biopsy (LB) assessment of liver fibrosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Fung, J., C. Lai, et al.** Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Fung, J., C. Lai, et al.** Predictive model for fibrosis and cirrhosis in chronic hepatitis B using liver stiffness measurement. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.


**Grünhage, F., J. Oldenburg, et al.** Transient elastography (FibroScan®) in patients with chronic hepatitis C virus infection and haemophilia A. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Grünhage, F., S. Schwartz, et al.** Genetic association study of profibrogenic gene variants using transient elastography for phenotypic characterization of liver fibrosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Hezode, C., L. Castera, et al.** Dynamics of liver stiffness during peginterferon Alpha-Ribavirin treatment in patients with chronic hepatitis C. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Huwart, L., C. Sempoux, et al.** Comparison of MR elastography, ultrasound elastography and APRI for the non-invasive assessment of liver fibrosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Kim, D., S. Kim, et al.** Usefulness of liver stiffness measurement in discriminating between chronic hepatitis B and compensated cirrhosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

**Kim, S., S. Ahn, et al.** Can liver stiffness predict the presence of Hepatocellular Carcinoma?. 58th Annual Meeting of the
American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Kim, S., S. Ahn, et al. The usefulness of measuring liver stiffness in predicting the development Hepatocellular Carcinoma. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Lucidarme, D., G. Forzy, et al. Interobserver reproducibility of liver stiffness measurement by transient elastography (FibroScan®). 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Lucidarme, D., J. Foucher, et al. The ratio interquartile range / Median value of liver stiffness measurement is a key factor of accuracy of transient elastography (FibroScan®) for the diagnosis of liver fibrosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Marino, N., S. Lo Caputo, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated epatotoxicity in HIV positive patients. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.


Nudo, C. G., L. Jeffers, et al. Correlation of laparoscopic liver biopsy to elasticity measurements (FibroScan®) in patients with chronic liver disease. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Poynard, T., P. Ingiliz, et al. Concordance between FibroTest® (FT) and Fibroscan® (FS): a new non-invasive methodology for improving accuracy in a world without a gold standard. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Rigamonti, C., M. Donato, et al. Transient elastography (TE) is an accurate tool in monitoring liver transplanted (LT) patients with recurrent hepatitis 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Seo, Y., E. Kim, et al. Liver stiffness measurement in patients with chronic hepatitis B is not as useful as that in patients with chronic hepatitis C for the assessment of liver fibrosis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Smirne, C., C. Colletta, et al. Regression of fibrosis among long-term responders to antiviral treatment for chronic viral hepatitis. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, November 2nd-6, 2007, Boston, MA, USA.


Seo, Y., Suh, S. et al. The result of liver stiffness measurement is influenced by the serum bilirubin level. 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.

Yoneda, M., H. Mawatari, et al. Transient elastography in patients with nonalcoholic fatty liver disease (NAFLD). 58th Annual Meeting of the American Association for the Study of Liver Disease, November 2nd-6, 2007, Boston, MA, USA.


Laharie, D., E. Chabrion, et al. Usefulness of FibroScan® for the follow up of patients treated with methotrexate.. 15th United European Gastroenterology Week, October 27-31st, Paris, France.


Marin, J. C., J. de La Cruz, et al. Prospective comparison between transient elastography (FibroScan®), APRI and Forns test for assessing liver fibrosis in patients with histological features of NAFLD. 42th Annual Meeting of the European Association for the Study of the Liver April 11-15, 2007, Barcelona, SPAIN.


Fung, J., C. L. Lai, et al. Large population study in liver stiffness measurement: prevalence of significant fibrosis and correlation with liver biochemistry in chronic hepatitis B. 42th Annual Meeting of the European Association for the Study of the Liver April 11-15, 2007, Barcelona, SPAIN.


Masuzaki, R., R. Tateishi, et al. Usefulness of transient elastography apparatus for assessing progression of chronic liver...

Castellares, C., L. Martin-Carbonero, et al. Transient elastography (FibroScan®) in the evaluation of recurrent disease after liver transplantation (LT) 57th Annual Meeting of the American Association for the Study of Liver Diseases October 27-31, 2006, Boston, MA, USA.


of Liver Disease. October 27-31, 2006, Boston, MA, USA.

Lemoine, M., S. Katsahian, et al. Liver stiffness measurement is correlated with hepatic venous pressure gradient in patients with uncomplicated alcoholic and/or hcv related-cirrhosis 57th Annual Meeting of the American Association for the Study of Liver Disease. October 27-31, 2006, Boston, MA, USA.


Gomez-Dominguez, E., J. Mendoza, et al. Efficiency of liver stiffness measurement (FibroScan®) for the follow up of patients with primary biliary cirrhosis. 57th Annual Meeting of the American Association for the Study of Liver Disease. October 27-31, 2006, Boston, MA, USA.


de Ledinghen, V., P. Barreiro, et al. Liver fibrosis estimation by Fibroscan® and biochemical markers according to HIV serostatus in two large cohorts of patients with chronic hepatitis C 57th Annual Meeting of the
American Association for the Study of Liver Disease. October 27-31, 2006, Boston, MA, USA.


Castera, L., J. Foucher, et al. Transient elastography (Fibroscan®) and FibroTest to assess liver fibrosis in inactive hepatitis B carriers: a prospective controlled study 57th Annual Meeting of the American Association for the Study of Liver Disease. October 27-31, 2006, Boston, MA, USA.


patients with chronic hepatitis C. 13th Conference on Retroviruses and Opportunistic Infections. February 5-8, 2006, Denver, Colorado, USA.


Liver Disease Nov. 11-15, 2005, San Francisco, USA.


de Ledinghen, V., L. Castera, et al. Repeated liver stiffness measurement using FibroScan” for the follow-up of untreated HCV patients and for the evaluation and monitoring of histological response in HCV responders: a prospective longitudinal study. 56th Annual Meeting of the American Association for the Study of Liver Disease Nov. 11-15, 2005, San Francisco, USA.


Kazemi, F., E. Pinto, et al. Liver stiffness measurement is highly predictive of the presence of oesophageal varices grade II-II in patients with cirrhosis. 55th Annual Meeting of the American Association for the Study of Liver Disease Oct. 29-Nov. 2nd, 2004, Boston, USA.


NATIONAL COMMUNICATIONS


Carrión, J. A. Alternativas a la biopsia hepática en pacientes con infección crónica por el virus de la hepatitis C. XXXIII Congreso Nacional de la Asociación Española para el Estudio del Hígado. February 20-22, 2008, Madrid, SPAIN.


Mendoza-Jiménez, J., E. Gómez-Domínguez, et al. Evaluación de la fibrosis hepática por elastografía de transición (FibroScan®) en
pacientes con enfermedad hepática crónica [Assessment of the hepatic fibrosis by transient elastography (FibroScan®) for patients with chronic liver disease]. XXXI Congreso Nacional de la Asociación Española para el Estudio del Hígado. February 15-17, 2006, Madrid, Spain.


Foucher, J., J. Vergniol, et al. Le FibroScan®, une nouvelle méthode non-invasive pour l’évaluation de la fibrose hépatique : résultats d’une étude prospective comparative avec la biopsie hépatique, le FibroTest, l’acide hyaluronique, la taux de prothrombine, le score APRI, le ratio ASAT/ALAT et le score de Forns [FibroScan® a novel non invasive method for the assessment of liver fibrosis: results of a prospective study comparing with liver biopsy, FibroTest, hyaluronic acid, prothrombin time, APRI score, ASAT/ALAT ratio and Forns score]. Journées Francophones de Pathologie Digestive, 29ème édition. April 2-6, 2005, Palais des Congrès, Paris, France.

Chanteloup, E., J. Vergniol, et al. Quelle est la signification clinique du FibroScan® au cours de la cirrhose ? [What is the clinical meaning of FibroScan® during the course of cirrhosis?]. Journées Francophones de Pathologie Digestive, 29ème édition. April 2-6, 2005, Palais des Congrès, Paris, France.


